Satri-cel: The World's First CAR-T Therapy Approved for Solid Tumors

This approval ends a decade-long limitation of CAR-T therapy to blood cancers and opens a new chapter for engineered cell therapy in solid tumors. Here is a complete breakdown of everything known about Satri-cel.

Approval and Regulatory Milestone

• Approval Date: June 22, 2026 .
• Regulator: China's National Medical Products Administration (NMPA) .
• Global Context: No CAR-T for solid tumors has been approved in the US, EU, or Japan. This makes Satri-cel the first regulatory validation that CAR-T technology can work commercially against solid malignancies .

Target Indication

Satri-cel is indicated for a precisely defined patient population:

• Biomarker-defined: Claudin18.2-positive, HER2-negative advanced gastric adenocarcinoma or GEJ adenocarcinoma .
• Line of therapy: Third-line or later — patients who have progressed on or after at least two prior systemic treatments .
• The Target: Claudin18.2 is a tight-junction protein highly expressed in gastric, pancreatic, and other gastrointestinal cancers but largely absent from normal tissues, making it an attractive solid-tumor target .

Clinical Trial Results (Phase 2 Pivotal Trial — CT041-ST-01)

The pivotal randomized Phase 2 trial (NCT04581473), published in The Lancet, provides the efficacy and safety basis for approval . Summary data from multiple sources:

Efficacy

• Primary endpoint met: Statistically significant improvement in progression-free survival (PFS) versus physician's choice of chemotherapy .
• In the intent-to-treat population: Median PFS was 3.25 months for Satri-cel vs. 1.77 months for the control group (HR, 0.366; 95% CI, 0.241–0.557; P < .0001) .
• Overall survival trend: Median OS was 7.92 months vs. 5.49 months (HR, 0.693; 95% CI, 0.457–1.051; one-sided P = .0416) .
• Phase 1 portion (all treated patients, N=98): Overall response rate (ORR) was 37.8% and disease control rate (DCR) was 75.5%; median PFS was 4.4 months and median OS was 8.8 months .
• In gastric cancer patients with measurable disease receiving monotherapy (n=47): ORR reached 57.4% and DCR reached 83.0%, with median PFS of 5.6 months and median OS of 10.2 months .

Safety

• Cytokine release syndrome (CRS): Occurred in 96.9% of patients, but all were Grade 1–2 (manageable) .
• Gastric mucosal injuries: Occurred in 8.2% of patients — mostly Grade 1–2, with one Grade 3 case of erosive gastritis that recovered .

Earlier-Line and Pipeline Data

• Earlier-line data: Long-term follow-up data (4.5+ years) from a small cohort receiving Satri-cel as sequential therapy after first-line treatment were presented at ASCO 2026. Among 4 patients with target lesions, the confirmed ORR was 100% .
• Pancreatic cancer pipeline: Preliminary Phase Ib data in adjuvant pancreatic cancer were presented at ESMO 2025, but this is not yet an approved indication .

Cost and Pricing

• List price: Approximately CNY 990,000 ($146,491 USD) per infusion, as reported by Caixin and Yicai Global .
• Total all-in cost for international patients: The expected range is $120,000–$170,000 USD, including apheresis, manufacturing, infusion, and hospital stay. This represents roughly 60–70% less than comparable CAR-T therapies in the US .
• Context: China now has 7 approved CAR-T therapies (vs. 6 in the US), all at substantially lower price points .

Availability for International Patients in Shanghai

• Designated International Center: Jiahui International Cancer Center (JICC) in Shanghai has completed Satri-cel administration protocol training and is positioned to receive patients from around the world .
• Eligibility criteria: International patients must meet the same CLDN18.2-positive, HER2-negative, and prior-therapy criteria as domestic patients .
• Contact Information: Jiahui Health's international office can be reached at internationaloffice@jiahui.com or via WhatsApp at +852 4619 1904 .
• Medical Visa: International patients typically require a medical visa (S2 or M visa) to enter China for treatment. JICC can provide invitation letters for visa applications .

Broader Significance for the Field

• Proof of concept for solid-tumor CAR-T: For nearly a decade, CAR-T therapy was confined to blood cancers. Satri-cel's approval proves that the technology can be effectively deployed against solid tumors by targeting lineage-specific surface antigens like Claudin18.2 .
• Regulatory first: No CAR-T for solid tumors has been approved in the US, EU, or Japan. This positions China — and specifically Shanghai's biotech ecosystem — at the forefront of the next wave of cell therapy .
• Platform validation: The same Claudin18.2-targeting approach is now being investigated in earlier lines of gastric cancer, pancreatic cancer, and potentially other CLDN18.2-expressing tumors .
• Cost-access paradigm: At roughly one-third the cost of US CAR-T therapies, Satri-cel could accelerate global medical tourism for cell therapy and pressure Western regulators and manufacturers on pricing .
• Pipeline effect: Several other companies (both Chinese and multinational) are now advancing CLDN18.2-directed CAR-T, bispecific antibodies, and antibody-drug conjugates, making this one of the most active targets in solid-tumor immuno-oncology .